-- iCAD Second Look CAD System Used to Generate Study Data -- NASHUA, N.H., Aug. 30 /PRNewswire-FirstCall/ -- iCAD(R), Inc. (NASDAQ: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier, today announced that its Second Look(R) CAD system was used in the "Evaluation of Breast Cancer with a Computer-Aided Detection System by Mammographic Appearance and Histopathology" study published in the September 1, 2005 edition of Cancer, a journal of the American Cancer Society. Study findings revealed that CAD technology effectively identified 98% of the microcalcifications, 95% of the invasive lobular carcinomas, 89% of the mixed mass/microcalcification lesions and 84% of the masses in 273 women with confirmed breast cancer. The study, which was based out of the Department of Radiology at The George Washington University Medical Center, concluded that CAD -- with an overall sensitivity of 89% -- represents a useful tool for the detection of breast cancer. According to the study, "On the basis of lesion histopathology, CAD showed a higher detection rate for DCIS and invasive lobular carcinomas. This indicates that CAD has an important role in reducing the occurrence of missed cancers, even with difficult to detect lesions, such as invasive lobular carcinoma." Dr. Rachel F. Brem, Director of Breast Imaging at The George Washington University Medical Center and study principle investigator said, "This study further demonstrates the potential of CAD for the improved diagnosis of breast cancer. It is particularly exciting as it demonstrates the effectiveness of CAD in cancers that are often difficult to detect mammographically such as invasive lobular carcinomas." The study was conducted over a four-year span from three institutions collecting one thousand consecutive screen-detected, biopsy-proven breast carcinomas. Every third tumor was selected until 275 consecutive carcinoma tumors were identified at random for system testing. Due to incomplete tumor data from two patients, the study was conducted on 273 carcinomas. From a consecutive series of 494 women with normal screenings, one hundred fifty-five mammograms were randomly selected for this study. For the 265 patients with cancer who had age data available, the mean age was 60.6 years and for the 154 women with normal mammograms with age data available, the mean age was 58.9. "Realizing the significant role that medical research plays in our healthcare system, iCAD applauds the patients and doctors who participate in such an important process," said W. Scott Parr, President and CEO at iCAD, Inc. "iCAD was privileged to take part in a study that further established the benefits of CAD for the early identification of breast cancer." According to the American Cancer Society there will be an estimated 211,240 new cases of breast cancer in 2005. Early detection of breast cancer can save lives and often permits less costly and less invasive cancer treatment options than when detected at a later stage. Described by leading health insurance providers in the United States as a 'standard of care' in large radiology practices and a 'medically necessary adjunct to mammography,' CAD continues to receive strong support from radiologists, the American College of Radiology and patient advocacy groups worldwide. About iCAD, Inc. iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan's Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by over one thousand women's healthcare centers worldwide. For more information, call 877 iCAD now or visit http://www.icadmed.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "anticipate," "likely," and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. iCAD and Second Look are registered trademarks of iCAD, Inc. For more information on iCAD, Inc., contact Kevin McGrath of Cameron Associates at 212 245 4577 or via email at . For all other inquires, contact Monica Pandolfi of SHIFT Communications at 617 681 1235 or via email at . DATASOURCE: iCAD, Inc. CONTACT: Kevin McGrath, +1-212-245-4577, , or Monica Pandolfi, +1-617-681-1235, , both for iCAD, Inc. Web site: http://www.icadmed.com/

Copyright